PE20121505A1 - Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina - Google Patents
Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histaminaInfo
- Publication number
- PE20121505A1 PE20121505A1 PE2012000880A PE2012000880A PE20121505A1 PE 20121505 A1 PE20121505 A1 PE 20121505A1 PE 2012000880 A PE2012000880 A PE 2012000880A PE 2012000880 A PE2012000880 A PE 2012000880A PE 20121505 A1 PE20121505 A1 PE 20121505A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- methylamine
- amine
- optionally substituted
- members
- Prior art date
Links
- 102000004187 Histamine H4 receptors Human genes 0.000 title abstract 2
- 108090000796 Histamine H4 receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 PYRROLIDINYL Chemical class 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 abstract 2
- LTBGBWFLLOAXTK-UHFFFAOYSA-N 2,2-diethyl-N-methylcyclopropan-1-amine Chemical compound CCC1(CC)C(C1)NC LTBGBWFLLOAXTK-UHFFFAOYSA-N 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382302 | 2009-12-23 | ||
| US30757910P | 2010-02-24 | 2010-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121505A1 true PE20121505A1 (es) | 2012-11-05 |
Family
ID=41667549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000880A PE20121505A1 (es) | 2009-12-23 | 2010-12-22 | Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8901146B2 (enExample) |
| EP (1) | EP2516420B8 (enExample) |
| JP (1) | JP5781537B2 (enExample) |
| KR (1) | KR101740085B1 (enExample) |
| CN (1) | CN102803248B (enExample) |
| AR (1) | AR079725A1 (enExample) |
| AU (1) | AU2010334804B2 (enExample) |
| BR (1) | BR112012017126A2 (enExample) |
| CA (1) | CA2785353C (enExample) |
| IL (1) | IL220554A (enExample) |
| MX (1) | MX345142B (enExample) |
| NZ (1) | NZ601021A (enExample) |
| PE (1) | PE20121505A1 (enExample) |
| RU (1) | RU2573828C2 (enExample) |
| TW (1) | TWI487697B (enExample) |
| UA (1) | UA107818C2 (enExample) |
| WO (1) | WO2011076878A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2493895T1 (sl) | 2009-10-29 | 2017-10-30 | Vectura Limited | Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze |
| UA121539C2 (uk) * | 2011-09-02 | 2020-06-25 | Інсайт Холдинґс Корпорейшн | Гетероцикліламіни як інгібітори рі3к |
| ES2946551T3 (es) | 2017-10-17 | 2023-07-20 | Palau Pharma S L U | Síntesis de compuestos de 4-aminopirimidina |
| GB201817047D0 (en) | 2018-10-19 | 2018-12-05 | Heptares Therapeutics Ltd | H4 antagonist compounds |
| JP2022165429A (ja) * | 2019-10-02 | 2022-11-01 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | ヒスタミンｈ４受容体調節作用を有する新規トリアジン誘導体 |
| CN117018194B (zh) * | 2023-07-26 | 2026-04-17 | 同济大学 | 毒蕈碱型受体5型受体拮抗剂的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200001256T2 (tr) * | 1997-11-04 | 2000-11-21 | Pfizer Products Inc. | Terapötik olarak aktif bileşimler. |
| US7737153B2 (en) * | 2002-10-28 | 2010-06-15 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
| JP4544999B2 (ja) * | 2002-11-25 | 2010-09-15 | 持田製薬株式会社 | ４−ヒドロキシピペリジン誘導体を有効成分とする呼吸器疾患治療剤 |
| EP1505064A1 (en) * | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
| WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| KR20080004585A (ko) * | 2005-04-08 | 2008-01-09 | 바이엘 파마슈티칼스 코포레이션 | 피리미딘 유도체 및 암의 치료에서의 이의 용도 |
| BRPI0615880A2 (pt) | 2005-09-13 | 2011-05-31 | Palau Pharma Sa | compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica |
| US7528143B2 (en) * | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| US20100035863A1 (en) | 2006-09-12 | 2010-02-11 | Ucb Pharma, S.A. | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| TW200904437A (en) | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
| PE20091035A1 (es) * | 2007-11-30 | 2009-07-16 | Palau Pharma Sa | Derivados de 2-aminopirimidina |
| WO2009077608A1 (en) | 2007-12-19 | 2009-06-25 | Palau Pharma, S. A. | 2 -aminopyrimidine derivatives as histamine h4 antagonists |
| US8431580B2 (en) * | 2007-12-21 | 2013-04-30 | Palau Pharma, S.A. | 4-aminopyrimidine derivatives as histamine H4 receptor antagonists |
-
2010
- 2010-12-22 MX MX2012007385A patent/MX345142B/es active IP Right Grant
- 2010-12-22 RU RU2012131223/04A patent/RU2573828C2/ru active
- 2010-12-22 JP JP2012545331A patent/JP5781537B2/ja not_active Expired - Fee Related
- 2010-12-22 PE PE2012000880A patent/PE20121505A1/es not_active Application Discontinuation
- 2010-12-22 TW TW099145246A patent/TWI487697B/zh active
- 2010-12-22 US US13/518,729 patent/US8901146B2/en active Active
- 2010-12-22 AR ARP100104921A patent/AR079725A1/es not_active Application Discontinuation
- 2010-12-22 BR BR112012017126A patent/BR112012017126A2/pt not_active Application Discontinuation
- 2010-12-22 WO PCT/EP2010/070562 patent/WO2011076878A1/en not_active Ceased
- 2010-12-22 UA UAA201207986A patent/UA107818C2/uk unknown
- 2010-12-22 AU AU2010334804A patent/AU2010334804B2/en active Active
- 2010-12-22 CN CN201080064585.3A patent/CN102803248B/zh active Active
- 2010-12-22 CA CA2785353A patent/CA2785353C/en active Active
- 2010-12-22 NZ NZ601021A patent/NZ601021A/en unknown
- 2010-12-22 EP EP10799037.6A patent/EP2516420B8/en active Active
- 2010-12-22 KR KR1020127019521A patent/KR101740085B1/ko active Active
-
2012
- 2012-06-21 IL IL220554A patent/IL220554A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2516420A1 (en) | 2012-10-31 |
| MX2012007385A (es) | 2012-08-15 |
| NZ601021A (en) | 2014-09-26 |
| MX345142B (es) | 2017-01-18 |
| RU2012131223A (ru) | 2014-02-10 |
| IL220554A (en) | 2016-08-31 |
| WO2011076878A1 (en) | 2011-06-30 |
| AU2010334804B2 (en) | 2015-04-02 |
| UA107818C2 (en) | 2015-02-25 |
| JP2013515698A (ja) | 2013-05-09 |
| CN102803248B (zh) | 2015-09-16 |
| CN102803248A (zh) | 2012-11-28 |
| RU2573828C2 (ru) | 2016-01-27 |
| BR112012017126A2 (pt) | 2017-10-31 |
| CA2785353C (en) | 2017-10-31 |
| US20130018031A1 (en) | 2013-01-17 |
| KR20120124421A (ko) | 2012-11-13 |
| AU2010334804A1 (en) | 2012-07-19 |
| CA2785353A1 (en) | 2011-06-30 |
| KR101740085B1 (ko) | 2017-05-25 |
| US8901146B2 (en) | 2014-12-02 |
| AR079725A1 (es) | 2012-02-15 |
| JP5781537B2 (ja) | 2015-09-24 |
| EP2516420B1 (en) | 2018-08-22 |
| TW201141840A (en) | 2011-12-01 |
| TWI487697B (zh) | 2015-06-11 |
| EP2516420B8 (en) | 2018-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091035A1 (es) | Derivados de 2-aminopirimidina | |
| PE20120321A1 (es) | Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20110061A1 (es) | Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20080186A1 (es) | Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2 | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| CR10784A (es) | Nuevos derivados de aminopirimidina como inhibidores de plki | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| PE20110703A1 (es) | Acidos naftilaceticos | |
| PE20140865A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| ATE544767T1 (de) | Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten | |
| PE20121158A1 (es) | Derivados de feniletinilo como moduladores alostericos positivos (map) | |
| PE20150220A1 (es) | Compuestos de tetrahidropirazolopirimidina | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PE20180177A1 (es) | Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20141681A1 (es) | Inhibidores de btk | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20140244A1 (es) | Composicion farmaceutica, metodos de tratamiento y usos de la misma | |
| DOP2013000103A (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
| BRPI0810402A2 (pt) | Derivados de pirrolidina como antagonistas duais dos receptores nk1/nk3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |